Listar PSB_Articles por autoría "49b390c5-e9bf-4155-8062-7fb366107193"
Mostrando ítems 1-3 de 3
-
Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials
Feliu-Soler, Albert; Cebolla Marti, Ausias; McCracken, Lance M.; D’Amico, Francesco; Knapp, Martin; López-Montoyo, Alba; Garcia-Campayo, Javier; Soler, Joaquim; Baños, Rosa Maria; Pérez-Aranda, Adrián; Andrés-Rodríguez, Laura; Rubio-Valera, María; Luciano, Juan Vicente Elsevier (2018-01)The term third-wave cognitive behavioral therapy (CBT) encompasses new forms of CBT that both extend and innovate within CBT. Most third-wave therapies have been subject to randomized controlled trials (RCTs) focused on ... -
Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study)
Sanabria-Mazo, Juan P.; García Forero, Carlos; Cristóbal-Narváez, Paula; García-Palacios, Azucena; Colomer-Carbonell, Ariadna; Pérez-Aranda, Adrián; Andrés-Rodríguez, Laura; McCracken, Lance M; D’Amico, Francesco; Estivill-Rodríguez, Pere; Carreras Marcos, Bernat; Montes-Pérez, Antonio; Esteve, Montserrat; Grasa, Mar; Rosa, Araceli; Cuesta-Vargas, Antonio I; Maes, Michael; Borràs, Xavier; Edo, Silvia; Sanz, Antoni; Feliu-Soler, Albert; Castaño Asins, Juan Ramon; Luciano, Juan Vicente BMJ Publishing Group (2020-07-23)Introduction: The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) ... -
Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)
Colomer-Carbonell, Ariadna; Sanabria-Mazo, Juan P.; Hernández-Negrín, Halbert; Borràs, Xavier; Suso-Ribera, Carlos; García-Palacios, Azucena; Muchart, Jordi; Munuera, Josep; D’Amico, Francesco; Maes, Michael; Younger, Jarred W.; Feliu-Soler, Albert; Rozadilla-Sacanell, Antoni; Luciano, Juan Vicente BMJ Publishing Group (2022-01)Introduction: There is evidence that low-dose naltrexone (LDN; <5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term ...